UK Innovation Map
Compare placesDifferent, not ranked.
Two or three clusters, read side by side across sectors, research, companies, capital, infrastructure, government designations and UKIZ relevance. There is no score and no ranking: British clusters are different from one another, not better or worse than one another.
Choose up to three clusters
- London
- Cambridge
- Oxford
- Manchester
- Birmingham & the West Midlands
- Bristol & Bath
- Sheffield & Rotherham
- Leeds & West Yorkshire
- Liverpool City Region
- Newcastle & the North East
- Teesside & the Humber
- Edinburgh
- Glasgow & the Central Belt
- Belfast
- Cardiff & South Wales
- Southampton & Portsmouth
- Cornwall & Plymouth
- Nottingham & Derby
- Norwich & the East
Side by side
| Dimension | CambridgeEast of England | Glasgow & the Central BeltScotland | Leeds & West YorkshireYorkshire and the Humber |
|---|---|---|---|
| Sectors | Life Sciences, Semiconductors, Engineering Biology, Artificial Intelligence Supporting: Quantum Technologies, Advanced Materials, AgriTech & FoodTech, Digital Technologies | Space, Semiconductors, Quantum Technologies, Advanced Manufacturing Supporting: Clean Energy, Digital Technologies, Robotics & Autonomous Systems | Life Sciences, Digital Technologies, Financial Technology Supporting: Artificial Intelligence, Advanced Manufacturing, Creative Industries |
| Research |
|
|
|
| Companies |
|
|
|
| Infrastructure |
University and institute laboratories, genomics and biomedical campus facilities, and semiconductor design capability. |
Satellite manufacturing capacity, nanofabrication cleanrooms and national manufacturing research facilities. | Not recorded on the map. Health data infrastructure, teaching hospitals and university research facilities. |
| Capital | Specialist deep tech and life science funds, university-linked funds, and corporate partners; strong at seed, thinner at growth stage relative to demand. | Public co-investment and specialist funds; hardware scale-up capital is scarce. | Financial services depth locally, but early-stage health technology capital remains limited. |
| Government programmes | No place-based designation recorded. | No place-based designation recorded. | No place-based designation recorded. |
| What exists | Extreme research density for its size: life sciences and genomics, semiconductor and processor IP, engineering biology and AI, with a mature spin-out culture and specialist investors who understand long timelines. | More small satellites built here than anywhere else in Europe, quantum imaging and nanofabrication research, and a large applied engineering, manufacturing and energy research base. | National health data organisations, medical technology, a large financial and professional services base and a research university with data and materials strength. |
| What's missing · UKIZ interpretation | Ownership retention. Discovery and early company formation work; the Series B onward stage frequently transfers ownership overseas. Laboratory and scale-up space, power and housing also constrain growth. | Downstream value. Satellites are manufactured here while much of the data and applications value is captured elsewhere. Scale-up finance for hardware is limited. | A clear route for companies to work with health data at scale, and clinical adoption pathways that move faster than pilot projects. |
| What could connect · UKIZ interpretation | Cambridge discovery connected to UK manufacturing and biomanufacturing capacity, and to later-stage domestic capital, so that value created here is realised here rather than acquired out of the country. | Glasgow manufacture connected to Cornwall launch and Earth observation, Harwell space applications and domestic data customers, forming one national space chain instead of four regional ones. | Leeds health data capability connected to Manchester clinical research and to medical technology manufacturing, giving companies discovery, evidence and production in one region. |
| UKIZ relevance | Cambridge produces intellectual property at a rate few places match, and loses ownership of too much of it at Series B. The proposed Oxford-Cambridge zone concentrates on commercialisation and retention rather than on more discovery. | Manufacture, launch and data are three different geographies in Britain. The proposed Scotland mission connects them deliberately. | Health data at population scale is a national asset. The proposed Manchester mission and Leeds capability are complementary rather than competing. |
| Last verified | 15 August 2026 | 15 August 2026 | 15 August 2026 |
Proposed by UKIZ · independent · not a government designation